Salmonella enterica serovar Paratyphi A (S. Paratyphi A)

Salmonella enterica serovar Paratyphi A is a Gram-negative, rod-shaped, flagellated bacterium that serves as the causative agent of paratyphoid fever, a systemic infection clinically similar to typhoid fever (CDC, 2023). As a human-restricted pathogen, it is transmitted through the fecal-oral route, primarily via contaminated food or water (WHO, 2023). Upon ingestion, the bacterium invades the intestinal epithelium and is subsequently internalized by macrophages, where it survives and replicates within Salmonella-containing vacuoles (SCVs) (NCBI, 2024). This intracellular lifestyle allows it to disseminate through the bloodstream to various organs, including the liver, spleen, and bone marrow, leading to systemic symptoms (StatPearls, 2023). Pharmacological intervention focuses on antimicrobial agents that target essential bacterial processes, such as DNA replication, protein synthesis, and cell wall integrity (PubChem, 2024). However, the rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains has complicated treatment strategies, necessitating the development of new antibiotics and effective conjugate vaccines (PubMed, 2023). Note: This entry represents a whole organism/pathogen rather than a single molecular target such as a protein or receptor.

Other names

Salmonella paratyphi ASalmonella enterica subsp. enterica serovar Paratyphi AS. Paratyphi AParatyphoid A bacillus

Antimicrobial agents target various essential bacterial processes: fluoroquinolones (e.g., Ciprofloxacin) inhibit DNA gyrase and topoisomerase IV to prevent DNA replication; macrolides (e.g., Azithromycin) bind to the 50S ribosomal subunit to inhibit protein synthesis; beta-lactams (e.g., Ceftriaxone, Ampicillin) inhibit penicillin-binding proteins to disrupt peptidoglycan cell wall synthesis (StatPearls, 2023; PubChem, 2024).